Coupling growth-factor engineering with nanotechnology for therapeutic angiogenesis

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Molecular Biology

Background:

• Therapeutic angiogenesis aims to manage ischemic diseases by promoting blood vessel formation.
• Current proangiogenic therapies face challenges in sustained delivery of angiogenic factors.
• Hepatocyte growth factor/scatter factor (HGF/SF) is a potent angiogenic agent.

Purpose of the Study:

• To investigate the therapeutic potential of a novel HGF/SF fragment, 1K1, for angiogenic applications.
• To evaluate the efficacy of nanoformulating 1K1 for sustained release and enhanced angiogenic outcomes.
• To explore the impact of nanoformulated 1K1 on downstream signaling pathways.

Main Methods:

• In vitro assays to assess angiogenic potential of 1K1.
• Zebrafish embryo and murine matrigel implant models to evaluate in vivo efficacy.
• Nanoformulation of 1K1 for sustained release.
• Analysis of downstream signaling, including the mitogen-activated protein kinase (MAPK) pathway.

Main Results:

• The 1K1 fragment demonstrated potent angiogenic activity in vitro and in vivo.
• Nanoformulation enabled sustained release of 1K1, prolonging its therapeutic effect.
• Sustained release of nanoformulated 1K1 modulated MAPK pathway signaling.
• Enhanced angiogenic outcomes were observed with nanoformulated 1K1 compared to non-formulated 1K1.

Conclusions:

• Nanoformulation of the 1K1 fragment offers a promising strategy for sustained therapeutic angiogenesis.
• This approach enhances angiogenic outcomes by temporally controlling downstream signaling.
• Combining protein engineering with nanotechnology presents new avenues for treating ischemic diseases.